Marshall Dennis E 4

What Happened

• Dennis E. Marshall, a director of BioLargo, Inc. (BLGO), was granted a derivative award on 2026-06-22 covering 40,909 shares. The filing lists the acquisition as a grant/award (code A) and shows no exercise price or immediate cash value (price reported as N/A).
• This grant was issued to replace an earlier option to purchase 10,000 shares that expired unexercised; the filing notes the replacement was made pursuant to a Compensation Committee plan. The filing does not report a cash purchase or any immediate sale of shares.

Key Details

• Transaction date reported: 2026-06-22; Form 4 filed: 2026-06-24.
• Transaction type: Grant/award of a derivative security (option) for 40,909 shares; exercise price not specified in the Form 4 (N/A).
• Footnotes: F1 — Grant replaces a 10,000-share option that expired unexercised due to an exercise-price discrepancy; F2 — total reflects expiration of those 10,000 options on June 20, 2026.
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: Form 4 was filed two days after the transaction date (reported on 6/24/2026 for a 6/22/2026 grant); the filing itself does not state a late filing.

Context

• This was an award of a derivative instrument (an option) rather than a market purchase or sale. Derivative grants give the holder the right to buy shares later under specified terms; they do not represent immediately acquired common stock or realized cash proceeds.
• Because this grant replaces an expired option, it appears to be a compensation-related adjustment rather than a straightforward insider purchase or sale. As always, such awards are common for board compensation and do not, by themselves, signal buy/sell intent.